myelodysplastic syndromes
Showing NaN - NaN of 66
Leukemia, Lymphoma, Myeloma Trial in Miami, Chicago, San Antonio (LLS Program)
Not yet recruiting
- Leukemia
- +4 more
- LLS Program
-
Miami, Florida
- +2 more
Feb 16, 2023
MDS Trial in Worldwide (Tamibarotene + Azacitidine, Tamibarotene Matched Placebo + Azacitidine)
Recruiting
- Myelodysplastic Syndromes
- Tamibarotene + Azacitidine
- Tamibarotene Matched Placebo + Azacitidine
-
Tucson, Arizona
- +87 more
Feb 2, 2023
Drug/Agent Toxicity by Tissue/Organ, Leukemia, MDS Trial in Chicago, Kankakee (amifostine trihydrate, cytarabine, mitoxantrone
Withdrawn
- Drug/Agent Toxicity by Tissue/Organ
- +3 more
- amifostine trihydrate
- +2 more
-
Chicago, Illinois
- +3 more
Jan 31, 2023
MDS Trial in Worldwide (Magrolimab, Azacitidine, Placebo)
Active, not recruiting
- Myelodysplastic Syndromes
- Magrolimab
- +2 more
-
Birmingham, Alabama
- +168 more
Dec 7, 2022
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, MDS Trial in Canada, United States (ASTX727)
Enrolling by invitation
- Acute Myeloid Leukemia
- +2 more
-
Fountain Valley, California
- +28 more
Nov 18, 2022
Hematopoietic Stem Cell Transplantation, Acute GVHD, Acute Myeloid Leukemia Trial in United States (CD24Fc, Placebo,
Terminated
- Hematopoietic Stem Cell Transplantation
- +4 more
- CD24Fc
- +3 more
-
Duarte, California
- +3 more
Oct 18, 2022
MDS, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute Trial in Worldwide (Azacitidine, Pevonedistat)
Completed
- Myelodysplastic Syndromes
- +2 more
-
Birmingham, Alabama
- +58 more
Aug 24, 2022
Relapsed or Refractory Acute Myeloid Leukemia (AML), Untreated AML, Other IDH1-mutated Positive Hematologic Malignancies Trial
Recruiting
- Relapsed or Refractory Acute Myeloid Leukemia (AML)
- +3 more
-
Birmingham, Alabama
- +26 more
Sep 12, 2022
MDS Trial in Worldwide (Oral Azacitidine, Durvalumab)
Active, not recruiting
- Myelodysplastic Syndromes
- Oral Azacitidine
- Durvalumab
-
New Haven, Connecticut
- +65 more
Aug 19, 2022
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Mixed Phenotype Acute Leukemia Trial in United States (drug,
Recruiting
- Acute Lymphoblastic Leukemia
- +7 more
- Busulfan
- +11 more
-
Duarte, California
- +26 more
Aug 11, 2022
Leukemia, Myeloid, Acute, MDS Trial in Worldwide (CC-90009)
Recruiting
- Leukemia, Myeloid, Acute
- Myelodysplastic Syndromes
-
New Haven, Connecticut
- +23 more
Aug 1, 2022
Leukemia, Myeloid, Acute, MDS Trial in Worldwide (Azacitidine, Durvalumab)
Active, not recruiting
- Leukemia, Myeloid, Acute
- Myelodysplastic Syndromes
- Azacitidine
- Durvalumab
-
New Haven, Connecticut
- +94 more
Jun 9, 2022
Leukemia, Myeloid, Acute, MDS, Leukemia, Myelomonocytic, Chronic Trial in Worldwide (H3B-8800 (RVT-2001))
Recruiting
- Leukemia, Myeloid, Acute
- +2 more
- H3B-8800 (RVT-2001)
-
Stanford, California
- +26 more
Mar 23, 2022
MDS, Secondary Acute Myeloid Leukemia (AML) Trial in United States (Clofarabine)
Completed
- Myelodysplastic Syndromes
- Secondary Acute Myeloid Leukemia (AML)
-
Chicago, Illinois
- +5 more
Mar 15, 2022
Leukemia, Myeloid, Acute, MDS Trial in Worldwide (CC-95251, Azacitidine)
Recruiting
- Leukemia, Myeloid, Acute
- Myelodysplastic Syndromes
-
Marina Del Rey, California
- +35 more
Mar 11, 2022
Acute Myeloid Leukemia, MDS Trial in United States (CG-806)
Recruiting
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
-
Duarte, California
- +9 more
Mar 4, 2022
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, MDS Trial in United States (CliniMacs TCR alpha-beta-Biotin system)
Enrolling by invitation
- Acute Lymphoblastic Leukemia
- +2 more
- CliniMacs TCR alpha-beta-Biotin system
-
Los Angeles, California
- +9 more
Feb 10, 2022
Acute Myeloid Leukemia, Acute Lymphoid Leukemia, MDS Trial in United States (TregGraft (Orca-T))
Recruiting
- Acute Myeloid Leukemia
- +4 more
- TregGraft (Orca-T)
-
Duarte, California
- +13 more
Oct 28, 2021
Brain and CNS Tumors, Chronic Myeloproliferative Disorders, Leukemia Trial in Chicago (Pemetrexed)
Completed
- Brain and Central Nervous System Tumors
- +10 more
-
Chicago, IllinoisRobert H. Lurie Comprehensive Cancer Center at Northwestern Univ
Sep 3, 2021
MDS, Leukemia, Myelomonocytic, Chronic Trial in Worldwide (Guadecitabine, Treatment Choice)
Completed
- Myelodysplastic Syndromes
- Leukemia, Myelomonocytic, Chronic
- Guadecitabine
- Treatment Choice
-
Duarte, California
- +95 more
Sep 1, 2021
Hematopoietic Stem Cell Transplantation, Acute GVHD, Acute Myeloid Leukemia Trial in United States (CD24Fc, Placebo,
Active, not recruiting
- Hematopoietic Stem Cell Transplantation
- +4 more
- CD24Fc
- +3 more
-
Duarte, California
- +3 more
Jul 19, 2021
Classical Hodgkin Lymphoma, B-cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia Trial in Chicago (Pembrolizumab)
Recruiting
- Classical Hodgkin Lymphoma
- +3 more
-
Chicago, IllinoisUniversity of Chicago
Jun 29, 2021
MDS Trial in France, Germany, United States (Oral rigosertib)
Completed
- Myelodysplastic Syndromes
- Oral rigosertib
-
Stanford, California
- +13 more
Jun 15, 2021
Connect® Myeloid Disease Registry
Recruiting
- Primary Myelofibrosis
- +2 more
-
Huntsville, Alabama
- +228 more
Mar 30, 2021
MDS Trial in Canada, United States (anti-thymocyte globulin)
Completed
- Myelodysplastic Syndromes
- anti-thymocyte globulin
-
Washington, District of Columbia
- +27 more
Jan 24, 2021